Piramal Pharma Q2 FY27 slides: 28% revenue growth, margins expand 350bps

Piramal Pharma reported Q2FY27 revenue of ₹2,617 crore, up 28% year over year, and EBITDA of ₹385 crore, up 72%, with EBITDA margin expanding 372 basis points to 14.7%. The company raised FY27 revenue-growth guidance to 19–20%; its stock rose 14.84% to $228.21 after the results. H1FY27 included a ₹64 crore net loss, improved 68% year over year, while net debt increased to ₹4,859 crore from ₹4,164 crore at March 2026.

Analysis

The key debate is whether the margin step-up is repeatable, not whether H1 growth was strong. CDMO mix shifting toward complex, on-patent work could support better pricing and customer stickiness; if sustained, that matters more than headline order inflows. The counterweight is that expansion and acquisitions are consuming capital while net debt rises, and reported profit remains thin. Track cash conversion, utilization, and incremental margins before extrapolating EBITDA growth into durable free cash flow.

The near-15% rally leaves little room for execution slippage near the 52-week high. In the next 1–3 months, guidance delivery, H2 order conversion, and Lexington ramp milestones are the catalysts; over 6–18 months, biologics/sterile capacity and differentiated CDMO mix could strengthen the franchise, but commissioning delays or weak utilization would turn fixed costs into a margin drag. Syngene and other Indian CDMOs may face tougher competition for complex programs if Piramal’s capacity and quality record translate into wins; this is a watch item, not evidence of near-term share loss.

Contrarian angle: the market may be rewarding operating leverage as though it were already structural, while underweighting balance-sheet intensity and the gap between EBITDA growth and net earnings/cash generation. Bayer distribution expiry appears unlikely to be a consolidated earnings catalyst given the stated low-margin exposure. AbbVie’s Indian ophthalmology JV is strategically useful, but JV economics should not be mistaken for direct consolidated AbbVie earnings exposure.

Key Decisions for Investors

• Do not chase the immediate gap higher in Piramal Pharma Limited. Keep it on a conditional long watchlist; initiate only after price digestion if the next update confirms CDMO conversion and cash generation, rather than relying on order inflows alone.
• For the next results, monitor segment EBITDA, operating cash flow, net debt, and capacity utilization—especially Lexington. Falsify the margin thesis if EBITDA margins retreat materially despite continued revenue growth, or if net debt rises without corresponding cash conversion.
• Treat Syngene and other Indian CDMO names as relative-performance watch items, not automatic shorts: a sustained increase in Piramal’s complex-program wins or utilization would be needed to establish competitive displacement.
• No direct trade in ABBV or BAYN from these disclosures alone: verify how the ophthalmology JV’s earnings are recognized for AbbVie and the actual post-expiry revenue/margin impact before changing exposure.